Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 15
2003 32
2004 17
2005 44
2006 54
2007 46
2008 55
2009 66
2010 60
2011 52
2012 47
2013 57
2014 72
2015 67
2016 74
2017 75
2018 69
2019 87
2020 80
2021 52
Text availability
Article attribute
Article type
Publication date

Search Results

951 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB, Kido A. Yang BB, et al. Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21456630 Review.
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases in more than a dose-proportional manner, suggesting that the clearance of pegfilgrastim decreases with increased dosing. ...As a resul …
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases i …
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V. Aapro M, et al. Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Support Care Cancer. 2017. PMID: 28842778 Free PMC article. Review.

It was agreed that pegfilgrastim and 11 days' filgrastim have similar efficacy and safety and that pegfilgrastim is preferred to < 11 days' filgrastim (and may be preferred to 11 days' filgrastim based on adherence and convenience); pegfilgrastim is not ap

It was agreed that pegfilgrastim and 11 days' filgrastim have similar efficacy and safety and that pegfilgrastim is preferred …
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Wang L, Baser O, Kutikova L, Page JH, Barron R. Wang L, et al. Support Care Cancer. 2015 Nov;23(11):3131-40. doi: 10.1007/s00520-015-2686-9. Epub 2015 Mar 29. Support Care Cancer. 2015. PMID: 25821144 Free PMC article. Review.
FN risk was also significantly reduced with pegfilgrastim PP versus filgrastim PP. Over all chemotherapy cycles, there was a numerical but statistically nonsignificant increase in the FN risk for lipegfilgrastim PP versus pegfilgrastim PP. Using MTC in cycle 1, PP w …
FN risk was also significantly reduced with pegfilgrastim PP versus filgrastim PP. Over all chemotherapy cycles, there was a numerica …
Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management.
Moore DC, Pellegrino AE. Moore DC, et al. Ann Pharmacother. 2017 Sep;51(9):797-803. doi: 10.1177/1060028017706373. Epub 2017 Apr 19. Ann Pharmacother. 2017. PMID: 28423916 Review.
OBJECTIVE: To review the incidence, risk factors, and management of pegfilgrastim-induced bone pain (PIBP). DATA SOURCES: PubMed was searched from 1980 to March 31, 2017, using the terms pegfilgrastim and bone pain. ...Naproxen compared with placebo demonstrated a r …
OBJECTIVE: To review the incidence, risk factors, and management of pegfilgrastim-induced bone pain (PIBP). DATA SOURCES: PubMed was …
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B. Bond TC, et al. J Oncol Pharm Pract. 2018 Sep;24(6):412-423. doi: 10.1177/1078155217714859. Epub 2017 Jun 14. J Oncol Pharm Pract. 2018. PMID: 28614980 Free PMC article. Review.
The current meta-analysis compared the neutropenia-related efficacy and safety of lipegfilgrastim to those of pegfilgrastim and filgrastim. Methods Embase was searched for trials examining the efficacy/safety of lipegfilgrastim, pegfilgrastim, or filgrastim. ...Indi …
The current meta-analysis compared the neutropenia-related efficacy and safety of lipegfilgrastim to those of pegfilgrastim and filgr …
Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report.
Romeo C, Li Q, Copeland L. Romeo C, et al. J Oncol Pharm Pract. 2015 Aug;21(4):301-4. doi: 10.1177/1078155214527858. Epub 2014 Mar 24. J Oncol Pharm Pract. 2015. PMID: 24664474
Traditional analgesics, such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, can be ineffective in severe pegfilgrastim-induced bone pain. With the high frequency of this adverse effect, it is clear that health practitioners need additional treatment options …
Traditional analgesics, such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, can be ineffective in severe pegfilgrastim
NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
Kirshner JJ, McDonald MC 3rd, Kruter F, Guinigundo AS, Vanni L, Maxwell CL, Reiner M, Upchurch TE, Garcia J, Morrow PK. Kirshner JJ, et al. Support Care Cancer. 2018 Apr;26(4):1323-1334. doi: 10.1007/s00520-017-3959-2. Epub 2017 Nov 16. Support Care Cancer. 2018. PMID: 29147854 Free PMC article. Clinical Trial.
PURPOSE: Mild-to-moderate bone pain is a commonly reported adverse event (AE) associated with pegfilgrastim. We evaluated the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on pegfilgrastim-associated bone pain. METHODS: In this open-labe …
PURPOSE: Mild-to-moderate bone pain is a commonly reported adverse event (AE) associated with pegfilgrastim. We evaluated the effect …
Pegfilgrastim.
Curran MP, Goa KL. Curran MP, et al. Drugs. 2002;62(8):1207-13; discussion 1214-5. doi: 10.2165/00003495-200262080-00012. Drugs. 2002. PMID: 12010086 Review.
Pegfilgrastim is a covalent conjugant of filgrastim (a recombinant human granulocyte colony-stimulating factor) and monomethoxypolyethylene glycol. ...Serum concentrations of pegfilgrastim remain elevated during neutropenia but decline when the neutrophil count incr
Pegfilgrastim is a covalent conjugant of filgrastim (a recombinant human granulocyte colony-stimulating factor) and monomethoxypolyet
Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature.
Hoshina H, Takei H. Hoshina H, et al. BMC Cancer. 2019 Dec 16;19(1):1217. doi: 10.1186/s12885-019-6403-9. BMC Cancer. 2019. PMID: 31842789 Free PMC article. Review.
Her treatment was initiated with docetaxel in combination with trastuzumab and pertuzumab followed by the supportive use of a long-acting G-CSF, pegfilgrastim. After administration of pegfilgrastim on day 5, the patient had an intermittent fever (body temperature up …
Her treatment was initiated with docetaxel in combination with trastuzumab and pertuzumab followed by the supportive use of a long-acting G- …
Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
Hoy SM. Hoy SM. BioDrugs. 2019 Feb;33(1):117-120. doi: 10.1007/s40259-019-00334-9. BioDrugs. 2019. PMID: 30701419 Review.
Pegfilgrastim-jmdb/MYL-1401H (FULPHILA) [hereafter referred to as pegfilgrastim-jmdb] is a biosimilar of the reference pegylated recombinant granulocyte colony-stimulating factor pegfilgrastim. ...The overall safety profile and immunogenic potential of the tw
Pegfilgrastim-jmdb/MYL-1401H (FULPHILA) [hereafter referred to as pegfilgrastim-jmdb] is a biosimilar of the reference pegylat
951 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page